Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is my cow to milk for 2020
Wow. How is there no one on the LJPC train here. I bypassed this so to speak a while back but had it ok n my watch because I follow Tang. This guy is gold. I'm trying to figure out the big drop to 3 before ori e started to come. Ack Jan 9th. So LJPC realized its earning, almost 30 million/7 million for the quarter for its product. That's pretty great, but not surprising for a Tang company. Tang also announced a big stake in ownership of shares, institutions are all in and the NDA filed but why the HUGE drop to 3 from the end of 2019 to early 2020??? Was it just really quiet?????? Was it the CEO leaving last year??? I will be a buyer at some point soon. Tan is the man
* * $LJPC Video Chart 02-04-2020 * *
Link to Video - click here to watch the technical chart video
LJPC Mar 20 '20 $4 Call LA JOLLA PHARMACEUTICAL CO
still holding one for earnings on Feb 4
Two Small Biotechs See Big Stock Purchases by Their Largest Holders -- Barrons.com
6:59 AM ET 1/15/20 | Dow Jones
* * $LJPC Video Chart 01-15-2020 * *
Link to Video - click here to watch the technical chart video
* * $LJPC Video Chart 01-14-2020 * *
Link to Video - click here to watch the technical chart video
(LJPC Mar 20 '20 $4 Call)
January 20, 2020 1:15 PM ET
Last Price 4.40 Today's Change + 1.38 (+45.70%)
Price Paid 1.00
Day's Gain 600.00
Total Gain$ 1722.40
Total Gain % 342.71
$LJPC Last Price $8.39 Today’s Change +1.39 (+19.86%)
La Jolla Pharmaceutical Shares Up 13% Premarket
7:50 AM ET 1/14/20 | Dow Jones
By Michael Dabaie
La Jolla Pharmaceutical Co. (LJPC) shares were up 13%, to $7.90, in premarket trading.
Company director Kevin C. Tang recently acquired about 3 million shares of the company's common stock, according to a filing with the Securities and Exchange Commission.
Write to Michael Dabaie at michael.dabaie@wsj.com
> Dow Jones Newswires
January 14, 2020 07:50 ET (12:50 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
$LJPC opened at $7.93 today!
7.67+0.67 (+9.57%)
As of 9:42AM EST.
Reason for the run up is Tang related- new 13d
* * $LJPC Video Chart 01-13-2020 * *
Link to Video - click here to watch the technical chart video
$LJPC 6.00 + 0.75 (+14.29%) off to the races!
$LJPC FILLING the gap as we speak and showing strength!
$LJPC Last Price $5.55
Today’s Change +0.300 (+5.71%)
$LJPC
Last Price 5.25
Today's Change + 1.36 (+34.96%)
Day's Range 4.08 - 5.35
Volume 4,884,807
La Jolla Pharmaceutical Company Announces Preliminary GIAPREZA(TM) (Angiotensin II) Net Sales for the Three and Twelve Months Ended December 31, 2019
8:00 AM ET 1/9/20 | GlobeNewswire
La Jolla Pharmaceutical Company Announces Preliminary GIAPREZA(TM) (Angiotensin II) Net Sales for the Three and Twelve Months Ended December 31, 2019
SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced preliminary GIAPREZA(TM) (angiotensin II) net sales for the three and twelve months ended December 31, 2019. For the three months ended December 31, 2019, preliminary GIAPREZA net sales were $7.2 million, up 71% from the three months ended December 31, 2018 and up 26% from the three months ended September 30, 2019. Vials of GIAPREZA shipped from distributors to hospitals (hospital demand) grew 74% for the three months ended December 31, 2019 as compared to the three months ended December 31, 2018 and 18% as compared to the three months ended September 30, 2019. For the twelve months ended December 31, 2019, preliminary GIAPREZA net sales were $23.1 million, up 129% from the twelve months ended December 31, 2018. La Jolla announced the commercial availability of GIAPREZA in the U.S. in March 2018.
As of December 31, 2019, La Jolla had approximately $87.8 million in cash and cash equivalents, compared to $104.8 million as of September 30, 2019. Net cash used in operating activities for the three months ended December 31, 2019 was approximately $17.0 million. La Jolla has no debt.
About GIAPREZA
In December 2017, GIAPREZA(TM) (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA mimics the body's endogenous regulatory peptide that is central to the renin-angiotensin-aldosterone system to increase blood pressure. Prescribing information for GIAPREZA is available at www.giapreza.com. GIAPREZA is marketed by La Jolla Pharmaceutical Company on behalf of La Jolla Pharma, LLC, its wholly owned subsidiary.
IMPORTANT SAFETY INFORMATION
Contraindications
None.
Warnings and Precautions
There is a potential for venous and arterial thrombotic and thromboembolic events in patients who receive GIAPREZA. Use concurrent venous thromboembolism (VTE) prophylaxis.
Adverse Reactions
The most common adverse reactions that were reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events.
Drug Interactions
Angiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARB) may reduce response to GIAPREZA.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
For additional information, please see Full Prescribing Information for the United States.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life- threatening diseases. In December 2017, GIAPREZA(TM) (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria. For more information, please visit www.ljpc.com.
Forward-looking Statements
This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: GIAPREZA(TM) (angiotensin II) sales; cash used in operating activities; regulatory actions relating to La Jolla's products by the U.S. Food and Drug Administration, European Medicines Agency and/or other regulatory authorities; the outcomes of clinical studies of La Jolla's products; and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.
Company Contacts
Sandra Vedrick
Senior Director, Investor Relations
La Jolla Pharmaceutical Company
Phone: (858) 207-4264 Ext: 1135
Email: svedrick@ljpc.com
and
Dennis Mulroy
Chief Financial Officer
La Jolla Pharmaceutical Company
Phone: (858) 207-4264 Ext: 1040
Email: dmulroy@ljpc.com
> Dow Jones Newswires
January 09, 2020 08:00 ET (13:00 GMT)
* * $LJPC Video Chart 01-09-2020 * *
Link to Video - click here to watch the technical chart video
still tracking LJPC?
* * $LJPC Video Chart 12-16-2019 * *
Link to Video - click here to watch the technical chart video
Werd up video guy! Too bad you’re here! Ambulance chaser! Lol!
* * $LJPC Video Chart 12-04-2019 * *
Link to Video - click here to watch the technical chart video
Looking at $3.25 on this one. Been on it since $2.53. We will see how soon it gets there. Look6at Friday
research on LJPC msmoneymoves.com/2019/12/01/la-jolla-pharmaceuticals-nasdaq-ljpc-swing-move/
Can someone in-the-know comment on the malaria indication?
Has everyone thrown in the towel on the malaria indication? The planet loses 400k people per year due to malaria, and 90% of the deaths come from children under the age of 5 in Africa.
* * $LJPC Video Chart 11-25-2019 * *
Link to Video - click here to watch the technical chart video
Safe to assume class actions to follow, thx Ljpc!!!
Had anybody tried IR for eps release?
I don’t think BO will ever happen with LJPC, but it’s PPS is heavily manipulated with an approved drug, partnership, and products in pipelines
Why LJPC doesn’t report financials for the 3Q?
Called IR yesterday asking same question but no call back yet
When is earning going to be released?
Someone know something about Financials after the close?
Based on the MACD, If history repeats itself, this is about to head north of $10. That's see what happens.
Snoof77
$LJPC KEEP ON WATCH-LIST FOR MONSTER BREAKOUT
OWAN AND CO RECENTLY ISSUED A BUY RATING AND A $25 PRICE TARGET ON NASDAQ:LJPC RESULTING IN A SPIKE IN PRICE AND VOLUME , WE EXPECT CONTINUATION IN THE DAYS AND WEEKS TO COME FOR SOME GREAT GAINS.
AVERAGE ANALYSTS PRICE TARGET $19.50
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
Just keep... Bleeding and Bleeding and Bleedingggggg, Go$LJPC
Anddd here comes the dump, was a good run ladies and gents.
Except, not all of us used margin to short.
Think Short Sellers Protest to much....Markets should be UP strong on Mex. deal ...Futures up Bigly
$LJPC Shorts likely to get squeezed hard before pull back that always comes after large gains...
Float is small and most shares held by institutional
Both Thursday and Fridays volume about 25 Times Average Daily Volume
Watch Volume close Pre Market Monday for hint of day to come...
* * $LJPC Video Chart 06-07-2019 * *
Link to Video - click here to watch the technical chart video
Will we have a power hour or flower hour ?
It's been a long time coming, hasn't it, SM? Nice to see. This stock was really beaten down.
LJCP I had traded in past months but todays action made me happy. It was perfect. I sold so I hope it does not run tomorrow. God bless, cj
congrats cj , your always in the big runners...
must be nice
$$$$$
BIG day today
for LJPC
Followers
|
116
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3141
|
Created
|
10/21/04
|
Type
|
Free
|
Moderators |
http://www.ljpc.com/
http://finance.yahoo.com/q/h?s=LJPC
La Jolla Pharmaceutical Company, a biopharmaceutical company, engages in the research and development of pharmaceutical products in the United States. Its principal product in development is Riquent, which is designed to treat lupus renal disease by preventing or delaying renal flares. Lupus is an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. Riquent is in Phase III clinical trial. The company also develops small molecules for the treatment of autoimmune diseases, and acute and chronic inflammatory disorders. La Jolla Pharmaceutical Company was founded in 1989 and is based in San Diego, California.
Riquent
Riquent (abetimus sodium) is a synthetic oligonucleotide conjugate composed of 4 identical strands of dsDNA (20BP in length) that are linked through a triethyleneglycol-based platform. It binds anti-dsDNA Ab and the complex is cleared via the immune system, thus ridding the body of one of the primary pathogenic antibody associated with lupus.
Lupus nephritis is a serious and potentially fatal orphan disease treated primarily by nephrologists and rheumatologists. Currently, there are no products specifically approved to treat lupus renal disease.
La Jolla Pharmaceutical is investigating Riquent for the treatment of lupus renal disease by preventing or delaying renal flares, a leading cause of sickness and death in lupus patients, and improving proteinuria. Proteinuria is an indicator of abnormal renal function. Riquent has been well tolerated in all 14 clinical trials, with no overall difference in the adverse event profiles for Riquent-treated patients compared with placebo-treated patients. Riquent specifically reduces circulating levels of anti-dsDNA antibodies and is also designed to specifically suppress the B cells that make these antibodies. Decreases in these antibodies are believed to be associated with a decreased risk of renal flare. Although clinical benefit has not yet been proven, Riquent treatment has significantly reduced these antibody levels in all clinical trials in which they were measured.
3 Month Chart
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |